KALA BIO, Inc.
No enriched coverage for $KALA in the last 7 days.
No SEC Form 4 filings for $KALA in the last 30 days.
See all $KALA insider activity →FingerMotion Inc. (FNGR) shares rose 18.1% to $0.16 in pre-market trading after announcing a $2.3M acquisition of Newbit Technology Inc. The company will purchase 100% of Newbit's outstanding shares on a cash-free, debt-free basis.
KALA Bio (KALA) shares surged 57.10% in after-hours trading after announcing a non-binding LOI to acquire a telehealth platform for $15M. The target generated $12.7M in trailing revenue and is cash-flow positive. KALA aims to close the deal by early 2027. The company's market cap is $9.74M, with shares down 99.34% over the past year.
KALA Bio (NASDAQ: KALA) signed a non-binding LOI to acquire a telehealth platform with $12.7M in trailing revenue and $48M in sales since 2023. The $15M deal, payable in cash and stock, is expected to close in late 2026 or early 2027, pending due diligence and approvals.
Recent KALA coverage spans mergers & acquisitions, financial news and corporate actions.
Shares expected to stay elevated on the acquisition news.
The acquisition adds a cash‑flow positive, revenue‑generating platform, likely supporting near‑term upside.
The acquisition could boost KALA's top‑line and diversify its AI‑health portfolio, but the cash‑stock mix may dilute existing shareholders.
Potential expansion of test distribution network.
Potential revenue upside if the reseller agreement is finalized.
AlphAI scores every news story that mentions KALA with an AI model for sentiment and relevance, and aggregates insider trades from KALA BIO, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
FingerMotion Inc. (FNGR) shares rose 18.1% to $0.16 in pre-market trading after announcing a $2.3M acquisition of Newbit Technology Inc. The company will purchase 100% of Newbit's outstanding shares on a cash-free, debt-free basis.
2 min readKALA Bio (KALA) shares surged 57.10% in after-hours trading after announcing a non-binding LOI to acquire a telehealth platform for $15M. The target generated $12.7M in trailing revenue and is cash-flow positive. KALA aims to close the deal by early 2027. The company's market cap is $9.74M, with shares down 99.34% over the past year.
2 min readKALA Bio (NASDAQ: KALA) signed a non-binding LOI to acquire a telehealth platform with $12.7M in trailing revenue and $48M in sales since 2023. The $15M deal, payable in cash and stock, is expected to close in late 2026 or early 2027, pending due diligence and approvals.
2 min readSeveral biotech and pharma companies received regulatory approvals. MESO, LLY, ANIP, GRAL, AZN, TLSI, ABBV, RHHBY, MRK, AMRX, and ABEO gained approvals for various treatments. ABBV and RHHBY also announced strategic partnerships. LLY, GRAL, and ABBV saw notable stock price changes.
3 min readKala Bio (KALA) and Virotek signed a non-binding LOI with a U.S. DNA testing platform to expand their genetic testing distribution. The deal, if finalized, would add a new reseller channel for Virotek's products and mark Kala's first non-ophthalmology reseller under their collaboration. Kala may earn profits or commissions if the deal closes. KALA stock closed at $0.56, down 6.51%.
1 min readKALA BIO (KALA) is seeking shareholder approval for a reverse stock split of up to 1-for-300 at its 2026 annual meeting on November 3. The company also plans to elect directors, vote on executive compensation, and ratify its auditor. KALA recently settled a $2.0 million loan with Oxford, removing debt from its balance sheet.
2 min readKALA BIO, Inc. (KALA) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. On September 3, 2026, KALA BIO, Inc. (“Kala” or the “Company”) entered into an Exclusive Distribution and Reseller Agreement (the “Agreement”) with Virotek, Inc. (“Virotek”), a Wyoming corporation. The following is a summary
4 min readKala Bio (KALA) and Virotek finalized an exclusive U.S. distribution agreement for Virotek's ophthalmology genetic tests. Kala will market, promote, and distribute the tests, with profit-sharing after Virotek recovers costs. The deal has a one-year term, with exclusivity contingent on commercial milestones. No revenue forecasts were provided. The U.S. genetic testing market was valued at $5.7B in 2025, projected to reach $6.9B in 2026.
1 min readKala Bio (KALA) and Virotek plan to form a U.S. distribution partnership for Virotek's ophthalmology genetic testing program. Kala will market and distribute the program, leveraging its existing eye care network. The deal is subject to definitive agreements and regulatory approvals, with a target timeline of 30 days. Both companies see this as a strategic fit, with Kala expanding its ophthalmic focus and Virotek gaining U.S. market access.
2 min readKALA BIO received a Nasdaq notice that its stock failed to meet the $1.00 minimum bid price, violating a listing rule. The company is ineligible for the standard compliance period due to a recent reverse split and will request a hearing. The stock will remain listed pending the decision.
1 min read
